REGENERON PHARMACEUTICALS, INC. Insider Trading for January 2014
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in REGENERON PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in REGENERON PHARMACEUTICALS, INC. for January 2014.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jan 29 2014 | REGN | REGENERON PHARMACE ... | Sanofi | 10% Owner | Buy | P | 279.26 | 45,628 | 12,742,267 | 15,974,873 | 15.9 M to 16 M (+0.29 %) |
Jan 29 2014 | REGN | REGENERON PHARMACE ... | Sanofi | 10% Owner | Buy | P | 278.50 | 18,379 | 5,118,590 | 15,929,245 | 15.9 M to 15.9 M (+0.12 %) |
Jan 29 2014 | REGN | REGENERON PHARMACE ... | Sanofi | 10% Owner | Buy | P | 277.45 | 12,806 | 3,553,035 | 15,910,866 | 15.9 M to 15.9 M (+0.08 %) |
Jan 29 2014 | REGN | REGENERON PHARMACE ... | Sanofi | 10% Owner | Buy | P | 276.27 | 3,141 | 867,757 | 15,898,060 | 15.9 M to 15.9 M (+0.02 %) |
Jan 29 2014 | REGN | REGENERON PHARMACE ... | Sanofi | 10% Owner | Buy | P | 275.17 | 3,181 | 875,328 | 15,894,919 | 15.9 M to 15.9 M (+0.02 %) |
Jan 29 2014 | REGN | REGENERON PHARMACE ... | Sanofi | 10% Owner | Buy | P | 273.44 | 100 | 27,344 | 15,891,738 | 15.9 M to 15.9 M (0.00 %) |
Jan 29 2014 | REGN | REGENERON PHARMACE ... | Sanofi | 10% Owner | Buy | P | 275.31 | 1,500 | 412,963 | 15,891,638 | 15.9 M to 15.9 M (+0.01 %) |
Jan 29 2014 | REGN | REGENERON PHARMACE ... | Sanofi | 10% Owner | Buy | P | 274.66 | 8,900 | 2,444,493 | 15,890,138 | 15.9 M to 15.9 M (+0.06 %) |
Jan 29 2014 | REGN | REGENERON PHARMACE ... | Sanofi | 10% Owner | Buy | P | 273.66 | 25,551 | 6,992,223 | 15,881,238 | 15.9 M to 15.9 M (+0.16 %) |
Jan 29 2014 | REGN | REGENERON PHARMACE ... | Sanofi | 10% Owner | Buy | P | 272.88 | 18,728 | 5,110,560 | 15,855,687 | 15.8 M to 15.9 M (+0.12 %) |
Jan 29 2014 | REGN | REGENERON PHARMACE ... | Sanofi | 10% Owner | Buy | P | 271.82 | 10,537 | 2,864,161 | 15,836,959 | 15.8 M to 15.8 M (+0.07 %) |
Jan 29 2014 | REGN | REGENERON PHARMACE ... | Sanofi | 10% Owner | Buy | P | 270.69 | 7,869 | 2,130,016 | 15,826,422 | 15.8 M to 15.8 M (+0.05 %) |
Jan 29 2014 | REGN | REGENERON PHARMACE ... | Sanofi | 10% Owner | Buy | P | 269.77 | 1,600 | 431,628 | 15,818,553 | 15.8 M to 15.8 M (+0.01 %) |
Jan 14 2014 | REGN | REGENERON PHARMACE ... | McCorkle Douglas S | VP Controller and A ... | Sell | S | 290.00 | 4,000 | 1,160,000 | 0 | 4 K to 0 (-100.00 %) |
Jan 14 2014 | REGN | REGENERON PHARMACE ... | GILMAN ALFRED G | Director | Option Exercise | M | 18.61 | 5,000 | 93,050 | 10,000 | |
Jan 14 2014 | REGN | REGENERON PHARMACE ... | GILMAN ALFRED G | Director | Sell | S | 300.00 | 5,000 | 1,500,000 | 0 | 5 K to 0 (-100.00 %) |
Jan 14 2014 | REGN | REGENERON PHARMACE ... | GILMAN ALFRED G | Director | Buy | M | 18.61 | 5,000 | 93,050 | 5,000 | 0 to 5 K |
Jan 06 2014 | REGN | REGENERON PHARMACE ... | SHOOTER ERIC M | Director | Option Exercise | A | 273.67 | 12,750 | 3,489,293 | 12,750 | |
Jan 06 2014 | REGN | REGENERON PHARMACE ... | BAKER CHARLES A | Director | Option Exercise | A | 273.67 | 12,750 | 3,489,293 | 12,750 | |
Jan 06 2014 | REGN | REGENERON PHARMACE ... | BAKER CHARLES A | Director | Gift | G | 0.00 | 590 | 0 | 0 | 590 to 0 (-100.00 %) |
Jan 06 2014 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Option Exercise | A | 273.67 | 12,750 | 3,489,293 | 12,750 | |
Jan 06 2014 | REGN | REGENERON PHARMACE ... | GILMAN ALFRED G | Director | Option Exercise | A | 273.67 | 12,750 | 3,489,293 | 12,750 | |
Jan 06 2014 | REGN | REGENERON PHARMACE ... | GILMAN ALFRED G | Director | Option Exercise | G | 0.00 | 3,500 | 0 | 8,912 | |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Option Exercise | A | 273.67 | 12,750 | 3,489,293 | 12,750 | |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Option Exercise | A | 273.67 | 12,750 | 3,489,293 | 12,750 | |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Option Exercise | A | 273.67 | 12,750 | 3,489,293 | 12,750 | |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Option Exercise | A | 273.67 | 12,750 | 3,489,293 | 12,750 | |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | POON CHRISTINE A | Director | Option Exercise | A | 273.67 | 12,750 | 3,489,293 | 12,750 | |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 30.63 | 48,000 | 1,470,240 | 4,736 | |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 277.50 | 100 | 27,750 | 25,447 | 25.5 K to 25.4 K (-0.39 %) |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 276.75 | 1,296 | 358,668 | 25,547 | 26.8 K to 25.5 K (-4.83 %) |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 276.04 | 6,893 | 1,902,744 | 26,843 | 33.7 K to 26.8 K (-20.43 %) |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 274.69 | 3,777 | 1,037,504 | 33,736 | 37.5 K to 33.7 K (-10.07 %) |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 273.77 | 5,602 | 1,533,660 | 37,513 | 43.1 K to 37.5 K (-12.99 %) |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 272.88 | 3,000 | 818,640 | 43,115 | 46.1 K to 43.1 K (-6.51 %) |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 276.09 | 22,007 | 6,075,913 | 46,115 | 68.1 K to 46.1 K (-32.31 %) |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 276.09 | 5,325 | 1,470,179 | 68,122 | 73.4 K to 68.1 K (-7.25 %) |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 30.63 | 48,000 | 1,470,240 | 73,447 | 25.4 K to 73.4 K (+188.63 %) |